Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Terminated Phase 2 Interventional Results available

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

NCT03655236
View directory record Official record
Conditions
Early Parkinson Disease
Interventions
K0706, placebo
Drug · Other
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
50 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Oct 20, 2026, 1:17 PM EDT
Not listed Phase 1 Interventional

Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

NCT05430009
View directory record Official record
Conditions
Liver Metastases, Non-small Cell Lung Cancer
Interventions
Liver SBRT, Pembrolizumab
Radiation · Drug
Lead sponsor
VA Ann Arbor Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 20, 2026, 1:17 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT07161414
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Recruiting Phase 2 Interventional

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

NCT05741164
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Propranolol, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

NCT03746106
View directory record Official record
Conditions
Vitamin B1 Deficiency, Thiamine Deficiency
Interventions
Trimethoprim, Metformin, Vitamin B1
Drug · Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

NCT03455764
View directory record Official record
Conditions
Melanoma
Interventions
MCS110, Dabrafenib, Trametinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Early Phase 1 Interventional

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02316834
View directory record Official record
Conditions
Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, BMN 673
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 2 Interventional

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011
View directory record Official record
Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Interventions
lorigerlimab, docetaxel, Prednisone
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older · Male only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants

NCT04545944
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vonoprazan, Midazolam
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition in Patients With Systolic Heart Failure

NCT01765400
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
Prasugrel 10 mg daily x 2 weeks, Clopidogrel 75 mg daily x 2 weeks
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 20, 2026, 1:17 PM EDT
Terminated Phase 1 Interventional

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

NCT00886457
View directory record Official record
Conditions
Cancer
Interventions
Decitabine and Pegylated Interferon-Alfa 2B
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 20, 2026, 1:17 PM EDT
Recruiting Not applicable Interventional

Inhibitory Mechanisms of Negative Urgency in Adolescent Suicidal Behavior

NCT05652153
View directory record Official record
Conditions
Suicidal Behavior, Suicidal Ideation, Negative Urgency, Cortical Inhibition, Depression
Interventions
Single-/paired-pulse transcranial magnetic stimulation
Other
Lead sponsor
University of Minnesota
Other
Eligibility
13 Years to 21 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 1 Interventional Results available

A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer

NCT02111187
View directory record Official record
Conditions
Prostate Cancer
Interventions
LDE225
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet

NCT00518765
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Aliskiren plus placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Oct 20, 2026, 1:17 PM EDT
Recruiting Phase 2 Interventional

Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery

NCT07020312
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Hip Arthroscopy
Interventions
Visualization training with neurofeedback, Standard post-surgical rehabilitation therapy
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

NCT01150812
View directory record Official record
Conditions
Thrombin Inhibition
Interventions
AZD8165
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 20, 2026, 1:17 PM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot Study

NCT01272388
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Not applicable Interventional

A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease

NCT00205231
View directory record Official record
Conditions
HIV Infections
Interventions
etanercept
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 20, 2026, 1:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

NCT02681302
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

NCT01776723
View directory record Official record
Conditions
Myelomonocytic Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 20, 2026, 1:17 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

NCT07003542
View directory record Official record
Conditions
Glioblastoma, Brain Tumor
Interventions
Sitagliptin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 1:17 PM EDT
Completed Phase 4 Interventional Results available

The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function

NCT03115853
View directory record Official record
Conditions
High Blood Pressure
Interventions
Aliskiren 150 mg, Placebo, HCTZ, Aliskiren 300 mg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 20, 2026, 1:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spinal Reflexes in Motor Skill Learning

NCT00076583
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 1:17 PM EDT